Both these authors contributed equally to this study.
Silencing invariant chain of DCs enhances Th1 response using small interfering RNA
Article first published online: 2 JAN 2013
© The Author(s) Journal compilation © 2007 International Federation for Cell Biology
Cell Biology International
Volume 31, Issue 7, pages 663–671, July 2007
How to Cite
Ke, S., Chen, X.-H., Li, H., Li, J.-F., Gu, Q.-L., Liu, B.-Y. and Zhu, Z.-G. (2007), Silencing invariant chain of DCs enhances Th1 response using small interfering RNA. Cell Biology International, 31: 663–671. doi: 10.1016/j.cellbi.2006.12.004
- Issue published online: 2 JAN 2013
- Article first published online: 2 JAN 2013
- Received 27 August 2006; revised 30 November 2006; accepted 15 December 2006
- Small interfering RNA;
- Invariant chain;
- Dendritic cells;
- Antitumor immunity
RNA interference (RNAi), which causes the degradation of any RNA in a sequence specific manner, is a posttranscriptional gene silencing mechanism. Targeting the invariant chain (Ii) in DCs has been used as an approach to enhance antitumor immunity. It is demonstrated in this article that transfection of H-2K DCs with siRNA specific for Ii gene can significantly knock down Ii. When exposed to TNF-α, immature DCs transfected with Ii siRNA can differentiate into mature DCs without reducing viability or IL-12p70 production. Ii siRNA-treated H-2K DCs exhibited an increased allostimulatory capacity in a lymphocyte proliferation assay. Furthermore, Ii siRNA-transfected H-2K DCs enhanced Th1 responses by increasing IFN-γ and decreasing IL-4 production, and much stronger cytotoxic activity was observed when DCs were co-transfected with Ii siRNA and an endogenous tumor antigen in vitro. Our findings indicate that silencing the Ii gene in DCs with siRNA may offer a potential approach to enhancing antitumor immunotherapy.